VALNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Valneva SE

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 17, 2026

$5.51−0.10 (-1.78%)

Close on Oct 19, 2026

Earnings

Quarterly results announced on Form 8-K, Item 2.02

Quarter	Reported	Time	Revenue	EPS (GAAP)	EPS (adjusted)
Q4 FY2025 Ended Dec 31, 2025	Mar 18, 2026	During market hours	–	–	–
Q1 FY2025 Ended Mar 31, 2025	May 7, 2025	During market hours	$49.20M	–	–
Q4 FY2024 Ended Dec 31, 2024	Mar 20, 2025	Before market open	–	–	–
Q4 FY2023 Ended Dec 31, 2023	Feb 15, 2024	Before market open	–	–	–
Q4 FY2022 Ended Dec 31, 2022	Feb 16, 2023	Before market open	–	–	–
Q1 FY2022 Ended Mar 31, 2022	May 5, 2022	After market close	–	–	–
Q4 FY2021 Ended Dec 31, 2021	Feb 4, 2022	Before market open	–	–	–

Company guidance

Outlook given with results on Mar 18, 2026, compared with the previous outlook

Measure	Period	Guidance	vs. prior
product sales	full-year 2026	145 to 160	New
Total revenues	full-year 2026	155 to 170	New

Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.

Press releases

Announcements Valneva filed with the SEC

Oct 15, 2026, 10:29 AM ET
Îlot Saint-Joseph, Bureaux Convergence, Bât. A,
EX-99.1 to Form 6-K
Oct 8, 2026, 7:57 AM ET
Îlot Saint-Joseph, Bureaux Convergence, Bât. A,
EX-99.1 to Form 6-K
Aug 14, 2026, 11:27 AM ET
Pfizer and Valneva’s Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency
EX-99.1 to Form 6-K
Aug 13, 2026, 10:27 AM ET
Îlot Saint-Joseph, Bureaux Convergence, Bât. A,
EX-99.1 to Form 6-K
Jul 22, 2026, 2:22 PM ET
Valneva to Report First Half 2026 Consolidated Financial Results on August 13, 2026
EX-99.1 to Form 6-K
Jun 25, 2026, 11:57 AM ET
Valneva Announces Successful Outcome of its
EX-99.1 to Form 6-K
Jun 5, 2026, 6:36 AM ET
Valneva Announces Availability of Documentation for its Annual General Meeting
EX-99.1 to Form 6-K
Jun 1, 2026, 10:00 AM ET
Valneva to Participate at U.S. and European Investor Conferences in June
EX-99 to Form 6-K
May 13, 2026, 4:49 PM ET
Îlot Saint-Joseph, Bureaux Convergence, Bât. A,
EX-99.1 to Form 6-K
May 13, 2026, 4:49 PM ET
Unaudited interim condensed consolidated financial statements as at March 31, 2026
EX-99.2 to Form 6-K
May 5, 2026, 12:09 PM ET
Valneva to Report First Quarter 2026 Consolidated Financial Results on May 13, 2026
EX-99.1 to Form 6-K
Apr 30, 2026, 5:11 PM ET
WHEREAS , the Company and the Investors are executing and delivering this Agreement in reliance upon the exemption from securities registration afforded by Section 4(a)(2) of the Securities Act and/or Regulation S promulgated thereunder;
EX-99.1 to Form 6-K
Apr 30, 2026, 5:11 PM ET
[Signature Page to Registration Rights Agreement] IN WITNESS WHEREOF, the parties have caused this Registration Rights Agreement to be duly executed as of date first written above. COMPANY: VALNEVA SE By: Name: Title:
EX-99.2 to Form 6-K
Apr 30, 2026, 5:11 PM ET
Îlot Saint-Joseph, Bureaux Convergence, Bât. A,
EX-99.3 to Form 6-K
Mar 26, 2026, 12:55 PM ET
Valneva to Participate in Multiple Events
EX-99.1 to Form 6-K
Mar 23, 2026, 4:06 PM ET
Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial
EX-99.1 to Form 6-K
Mar 18, 2026, 11:21 AM ET
Valneva Reports Full Year 2025 Audited Consolidated Financial Results
EX-99.1 to Form 6-K
Mar 9, 2026, 12:50 PM ET
Valneva to Report Full Year 2025 Consolidated Financial Results
EX-99.1 to Form 6-K
Mar 2, 2026, 11:50 AM ET
Valneva to Participate in Upcoming Investor Conferences
EX-99.1 to Form 6-K
Feb 19, 2026, 6:19 AM ET
Valneva Reports Preliminary Unaudited 2025 Revenue and Cash and Provides 2026 Outlook
EX-99.1 to Form 6-K
Feb 13, 2026, 11:51 AM ET
Valneva Provides Update on Recommendations for Use of IXCHIQ ® in the United Kingdom
EX-99.1 to Form 6-K
Feb 3, 2026, 9:17 AM ET
Valneva and Instituto Butantan Announce Initiation of a Pilot Vaccination Campaign in Brazil with Single-Shot Chikungunya Vaccine IXCHIQ ®
EX-99.1 to Form 6-K
Jan 20, 2026, 9:50 AM ET
Valneva Provides Update on Chikungunya Vaccine IXCHIQ ®
EX-99 to Form 6-K
Jan 9, 2026, 10:55 AM ET
Valneva to Meet with Investors during the J.P. Morgan Healthcare Conference
EX-99.1 to Form 6-K
Dec 31, 2025, 11:53 AM ET
Valneva and Serum Institute of India Announce Discontinuation of Chikungunya Vaccine License Agreement
EX-99.1 to Form 6-K
Dec 11, 2025, 6:26 AM ET
Valneva Reports Positive Final Phase 2 Antibody Persistence and Safety Results in Children for its Chikungunya Vaccine IXCHIQ ®
EX-99.1 to Form 6-K
Nov 28, 2025, 6:44 AM ET
Valneva to Further Consolidate its Operations in France
EX-99.1 to Form 6-K
Nov 26, 2025, 8:20 AM ET
Campus Bio-Ouest | 6, Rue Alain Bombard
EX-99.1 to Form 6-K
Nov 20, 2025, 6:04 AM ET
Campus Bio-Ouest | 6, Rue Alain Bombard
EX-99.1 to Form 6-K
Nov 20, 2025, 6:04 AM ET
Unaudited interim condensed consolidated financial statements as at September 30, 2025
EX-99.2 to Form 6-K
Nov 4, 2025, 6:28 AM ET
Valneva Reports Positive Results for Phase 1 Trial of Second-Generation Zika Vaccine Candidate
EX-99.1 to Form 6-K
Oct 6, 2025, 12:50 PM ET
Valneva Strengthens Financial Position by Refinancing Debt with Pharmakon Advisors and Provides Business Updates
EX-99.1 to Form 6-K
Oct 6, 2025, 12:02 PM ET
Valneva Reports 95% Seroresponse Four Years After Single Shot of Chikungunya Vaccine IXCHIQ ®
EX-99.1 to Form 6-K
Sep 3, 2025, 8:25 AM ET
Valneva Reports Further Positive Phase 2 Safety and
EX-99.1 to Form 6-K
Aug 25, 2025, 6:23 AM ET
Valneva Announces FDA’s Decision to Suspend License of Chikungunya Vaccine IXCHIQ ® In the U.S.
EX-99.1 to Form 6-K
Aug 18, 2025, 9:45 AM ET
Valneva’s Chikungunya Vaccine IXCHIQ ® Now Authorized in Canada for Individuals Aged 12 and Older
EX-99.1 to Form 6-K
Aug 12, 2025, 9:44 AM ET
Campus Bio-Ouest | 6, Rue Alain Bombard
EX-99.1 to Form 6-K
Aug 7, 2025, 8:26 AM ET
Valneva Announces Removal of FDA-Recommended Pause on Use of Chikungunya Vaccine IXCHIQ ® in Elderly and Updates to the Prescribing Information
EX-99.1 to Form 6-K
Jul 11, 2025, 2:04 PM ET
Valneva Announces Lifting of European Medicines Agency’s Temporary Restriction on Use of Chikungunya Vaccine IXCHIQ® in Elderly
EX-99.1 to Form 6-K
Jun 26, 2025, 7:30 AM ET
Valneva Announces Exclusive Vaccine Marketing and Distribution Agreement for Germany with CSL Seqirus
EX-99.1 to Form 6-K

Where these numbers come from

Parsed from the XBRL in Valneva's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is VALN.

Revenue growth-27.2% · median 30.5%

Gross margin16.4% · median 89.1%

Operating margin-80.5% · median -56.6%

Company	Revenue	Growth
NVAX	$413.80M	-61.6%
VIR	$303.23M	+1495.9%
VXRT	$243.06M	+201.1%
VALN	€142.94M	-27.2%
AGEN	$132.69M	+30.5%
IVVD	$58.37M	+26.3%

Company

Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
Fiscal year ends: December 31
Employees: 140
Held by institutions: 2.2%
Auditor: Deloitte & Associes
SEC CIK: 1836564

Advertisement
300 × 250